| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Outline of Final Research Achievements |
It is increasing the emergence of drug-resistant bacterial strains that are resistant to marketed antibacterial agents, and increasingly has be reported that death caused by drug-resistant strains. Thus, with the aim of producing new antibacterial agents which have effective for multiple-drug-resistant bacteria, I have achieved study on the synthesis of unique compound which have been designed based on the diterpenoid preuromutilin, was isolated from basidiomycete species, and have evaluated their antibacterial activities. As a consequence, I found compounds that show equal potent antibacterial activities against S. aureus FDA209P and S. aureus KMP9, and also have excellent water-soluble that can be developed as an injection.
|
